The relationship between PD-L1 expression and activity of anti-PD-1 antibodies is unclear. Now, in a phase I clinical trial of MK-3475—a humanized monoclonal IgG4 antibody against PD-1—tumour expression levels of PD-L1 were shown to correlate with tumour response and progression-free survival (PFS) in 135 patients with melanoma treated with the agent. The median PFS was 36 weeks and the 6-month overall survival rate was 89%. In a separate study of 38 patients with non-small-cell lung cancer (NSCLC), the median PFS was 9 weeks, and 24% of patients had a response according to immune-related response criteria. These preliminary results indicate that PD-L1 is an important biomarker for patients with melanoma and NSCLC treated with MK-3475.
References
Daud, A. I. et al. Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): correlation of tumor PD-L1 expression with outcome [abstract]. Proc. Ann. Meeting AACR CT104 (2014)
Gandhi, L. et al. MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expression [abstract]. Proc. Ann. Meeting AACR CT105 (2014).
Rights and permissions
About this article
Cite this article
PD-1 targeting: correlating marker expression and outcome. Nat Rev Clin Oncol 11, 302 (2014). https://doi.org/10.1038/nrclinonc.2014.76
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2014.76
